We would love to hear your thoughts about our site and services, please take our survey here.
Probably the lack of any Dec update too...
Feels like a safe entry point here :)
Hey, what's behind the recent drop here?
That's last years earnings too- this year closer to 50%
Hi, just looking at this... having glanced at the numbers I cant quite believe how cheap it is! I guess that's the high gold price a year ago? 2.11c EPS in H1... gold price down around 5% but gold yield up about 5% should mean full year earnings around 4c or just over, or 3p at current exchange rates... that's a potential dividend of 1.5p, nearly 10%! Plus increased PE rations, PEG & all that good stuff. The recent riots seem to have blown over... what else am I missing?
Hi chaps, I'm out now (at a fairly big loss!), i'll look to come back in in around 6-12 months when things should start looking more interesting- gla
Solid results, but not much to excite... nothing new really. I think I'm going to sit on the side & watch for the next 12-18 months, but i can't see it breaking out of the 5-7 range without something like a takeover bid... funny how the market values a business isn't it? Next post a result of -94% profit and the share price rises 4%... this lot post +20% profit, and the share price droops like last weeks celery! I think this one will start to agitate in the 12-18 month timescale... Happy to be proved wrong, and i'll hold for now & topup on any weakness
Relax, this lot generate as much cash as Boohoo... the share price is easy to manipulate before staturatory results, particularly one where a 9-fold increase in EPS will be announced. (Some providers still quote the reported EPS of 4p, which incorrectly gives a PE/Ratio of 150odd, whereas others such as Hargreaves Lansdowne use the adjusted EPS of 55p for last year, giving a ratio of around 12 times). Adjusted EPS is likely to come in around 65p-70p, meaning the PE ratio is only 10x at the moment, which really is bargain basement for a business still in growth, albeit slightly slower than previously. Historically its traded around the 18x level, which would see a share price of £12.50... so wheres the risk at £6.50? Better to come back and look again in 3 months time after results have been announced, and we get a view on outlook for this FY
share price drops before huge increase in earnings announced... haven't ever seen that before *rolls eyes*. I called it a few months ago- price won't increase until earnings are announced - probably at 7:45am on the 17th Sep lol. DYOR, im in and will topup when I can
all shares are volatile, but if you see long-term value you buy.... we will know more on long-term value in Septembers results release. And in terms of this morning, market makers probably spotted a load of stop-loss orders set at £7, which have now been robbed- classic
This one was always going to suck. Plenty of positives, but market wont rebalanced this until full yr results in September, when we get a proper view on earnings. Revenue, profit, debt all positives, offset against an 'average' forecast... Good time to top up I think, but won't expect this to go anywhere but down/flat until September
Next week- probably Wed/Thur based on last year... should change sentiment either posumitively or negatively! I'm hoping for organic growth of 9%+, debt at £360m max, and some positive noises on Proluken. Fingers crossed!
Yeah, adjusted EPS is looking likely to come in around 75p for the full year, so at 15x PE (which is a tad lower than they've historically been), that gives £11.25... but that's not exactly a knockout bid - I'd expect them to pay around 18x, which is £13.50... but it's old news, so may not happen. Let's just see what FY19 results bring
I just received a contract note on my ISA telling me that Clinigen have confirmed a bid received... somethings definitely happening. I suspect if there is a buyer, they'll want it done before mid-July results are out, but who knows for sure!
It's been fairly well covered below... debt is a little high, but they've just finished paying off some lumpy acquisition-related payments, and with EBITDA likely to be in the region of £130m, could pay it down fairly quickly. Organic growth was 9% in H1, increasing to at least 12% in Q3 based on their last trading statement. They've announced they have signed quite a few deals recently too, including the "largest one in our history". Lastly 3 directors bought shares recently, so all in all, great buy at these levels
Perhaps the appointment of the joint broker has something to do with it?
Hi all, new holder here, fairly small. I intend to hold for the longer term. I also hold Clinigen and Lidco as I'm a fan of the sector. Can anyone give me a balanced view on this one? I have had a read through recent RNS etc... seems a good growth story, with a hold back on profitability & cashflow, but looks like they are close to turning a corner?